Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03238703 |
|
Recruitment Status :
Withdrawn
(Administrative closure based on sponsor recommendation, prior to subject enrollment)
First Posted : August 3, 2017
Last Update Posted : December 27, 2018
|
Sponsor:
Fred Hutchinson Cancer Research Center
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Fred Hutchinson Cancer Research Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This pilot clinical trial studies how well endocrine therapy works in treating patients with HER2 negative, low risk breast cancer. Estrogen can cause the growth of breast cancer cells. Endocrine therapies such as aromatase inhibitors and selective estrogen receptor modulators may lessen the amount of estrogen made by the body.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| HER2/Neu Negative Invasive Breast Carcinoma Postmenopausal Stage 0 Breast Cancer Stage IA Breast Cancer | Drug: Anastrozole Drug: Exemestane Other: Laboratory Biomarker Analysis Drug: Letrozole Other: Quality-of-Life Assessment Other: Questionnaire Administration Drug: Tamoxifen Citrate Drug: Toremifene Citrate | Phase 4 |
PRIMARY OBJECTIVES:
I. To estimate the conversion rate from a standard low-toxicity approach to guideline-directed therapy which includes surgery +/- radiation therapy as a result of progression of disease or patient/provider choice.
II. To examine factors that might differ between those who convert from the low-toxicity approach to the guideline-directed therapy and those do not convert.
SECONDARY OBJECTIVES:
I. To measure the safety and clinical effectiveness of systemic endocrine therapy used in a prolonged neoadjuvant fashion.
II. To evaluate the impact of risk-stratified care in Quality-Adjusted Life Years (QALY) and QALY gains.
III. To estimate the cost savings of indefinitely delaying surgery and radiation in favor of systemic endocrine therapy alone.
OUTLINE:
Patients receive exemestane orally (PO) once daily (QD), anastrozole PO QD, letrozole PO QD, tamoxifen citrate PO QD, or toremifene citrate PO QD at the discretion of the treating physician. Treatment continues in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up periodically.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 0 participants |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | An Investigator Initiated Registry of Simple Oral Therapy for Low Risk Breast Cancer (SOLR) |
| Estimated Study Start Date : | September 1, 2018 |
| Estimated Primary Completion Date : | March 14, 2023 |
| Estimated Study Completion Date : | March 14, 2025 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Breast cancer
MedlinePlus related topics:
Breast Cancer
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Treatment (AI, SERM)
Patients receive exemestane PO QD, anastrozole PO QD, letrozole PO QD, tamoxifen citrate PO QD, or toremifene citrate PO QD at the discretion of the treating physician. Treatment continues in the absence of disease progression or unacceptable toxicity.
|
Drug: Anastrozole
Given PO
Other Names:
Drug: Exemestane Given PO
Other Names:
Other: Laboratory Biomarker Analysis Correlative studies Drug: Letrozole Given PO
Other Names:
Other: Quality-of-Life Assessment Ancillary studies
Other Name: Quality of Life Assessment Other: Questionnaire Administration Ancillary studies Drug: Tamoxifen Citrate Given PO
Other Names:
Drug: Toremifene Citrate Given PO
Other Names:
|
Primary Outcome Measures :
- Conversion from oral endocrine therapy for any reason to guideline-directed therapy [ Time Frame: Up to 5 years ]Includes clinical or radiographic progression, patient preference, endocrine therapy intolerance or toxicity, or death from any cause. Descriptive statistics will be summarized among all patients and patients within each of the two groups (stay with oral therapy vs conversion due to any causes).
Secondary Outcome Measures :
- Advanced imaging (if performed on any subset of patients) [ Time Frame: Up to 5 years ]Will be compared to a concurrent group of patients managed in the conventional manner with upfront surgery +/‐ radiation therapy followed by systemic endocrine therapy. Descriptive statistics will be summarized among all patients and patients within each of the two groups (stay with oral therapy vs conversion due to any causes).
- Cost-effectiveness and patient-centeredness outcomes defined as financial toxicity and solubility, quality of life (physical, mental, emotional changes) on endocrine therapy, and, access to support services [ Time Frame: Up to 5 years ]Comparisons will be made to historical benchmarks for similar patients managed in a conventional locoregional manner for early‐stage breast cancer. Descriptive statistics will be summarized among all patients and patients within each of the two groups (stay with oral therapy vs conversion due to any causes).
- Effect of age [ Time Frame: Up to 5 years ]Will be compared to a concurrent group of patients managed in the conventional manner with upfront surgery +/‐ radiation therapy followed by systemic endocrine therapy. Descriptive statistics will be summarized among all patients and patients within each of the two groups (stay with oral therapy vs conversion due to any causes).
- Effect of comorbidity severity interaction [ Time Frame: Up to 5 years ]Will be compared to a concurrent group of patients managed in the conventional manner with upfront surgery +/‐ radiation therapy followed by systemic endocrine therapy. Descriptive statistics will be summarized among all patients and patients within each of the two groups (stay with oral therapy vs conversion due to any causes).
- Effect of type of endocrine therapy type (selective estrogen receptor modifier versus aromatase inhibitor) [ Time Frame: Up to 5 years ]Will be compared to a concurrent group of patients managed in the conventional manner with upfront surgery +/‐ radiation therapy followed by systemic endocrine therapy. Descriptive statistics will be summarized among all patients and patients within each of the two groups (stay with oral therapy vs conversion due to any causes).
- Effects emanating from tertiary care [ Time Frame: Up to 5 years ]Will be compared to a concurrent group of patients managed in the conventional manner with upfront surgery +/‐ radiation therapy followed by systemic endocrine therapy. Descriptive statistics will be summarized among all patients and patients within each of the two groups (stay with oral therapy vs conversion due to any causes).
- Progression of disease while on primary endocrine therapy, as measured objectively by routine diagnostic breast imaging (mammography and/or ultrasound) [ Time Frame: Up to 5 years ]Descriptive statistics will be summarized among all patients and patients within each of the two groups (stay with oral therapy vs conversion due to any causes).
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 60 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Able to provide written informed consent
-
A diagnosis of invasive breast cancer, with or without an in situ component, that is:
- Originally identified by screening mammography
- Characterized by standard diagnostic mammography +/- breast ultrasound
- Clinically node negative
- Confirmed by breast magnetic resonance imaging (MRI) in a facility that maintains active American College of Radiology (ACR) accreditation to be of low clinical stage (=< 2 cm, node negative, unifocal invasive)
- Estrogen receptor (ER) and progesterone receptor (PR) Allred scored, each > 5/8
- Her2 negative using American Society of Clinical Oncology (ASCO)-College of American Pathologists (CAP) guidelines
- ki‐67 proliferation scored, < 20%
- Clinical Nottingham grade 1 or 2
- Scored on the MammaPrint 70-gene breast cancer recurrence assay as low risk
- Prior to the discovery of the breast cancer, clinically post‐menopausal as defined as: i) one or more years from last menses; or ii) history of oophorectomy; or iii) follicle stimulating hormone (FSH) test result in the post-menopause reference range
- Willing to accept oral endocrine therapy with a third generation aromatase inhibitor (AI) or selective estrogen receptor modifier (SERM)
- Willing to undergo routine surveillance with breast ultrasound and/or mammography
Exclusion Criteria:
- Known contraindication to aromatase inhibitor or SERM therapy
- Pregnant at time of or within prior year of diagnosis
- Clinically detected or palpable disease prior to biopsy in either breast or ipsilateral axilla
- Prior history of invasive breast cancer or ductal breast carcinoma in situ (DCIS)
- Prior use of aromatase inhibitor therapy apart from assisted reproduction
- Prior use of SERM
- Unmanaged/uncontrolled mental health disorder
- Life expectancy < 6 months (m) for any cause
- Biopsy confirmed multifocal, multicentric, or contralateral disease that is invasive or non-invasive
- DCIS with focal invasion
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03238703
Locations
| United States, Washington | |
| Fred Hutch/University of Washington Cancer Consortium | |
| Seattle, Washington, United States, 98109 | |
Sponsors and Collaborators
Fred Hutchinson Cancer Research Center
National Cancer Institute (NCI)
Investigators
| Principal Investigator: | Vijayakrishna Gadi | Fred Hutch/University of Washington Cancer Consortium |
| Responsible Party: | Fred Hutchinson Cancer Research Center |
| ClinicalTrials.gov Identifier: | NCT03238703 History of Changes |
| Other Study ID Numbers: |
9764 NCI-2017-00724 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) 9764 ( Other Identifier: Fred Hutch/University of Washington Cancer Consortium ) P30CA015704 ( U.S. NIH Grant/Contract ) |
| First Posted: | August 3, 2017 Key Record Dates |
| Last Update Posted: | December 27, 2018 |
| Last Verified: | December 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Breast Neoplasms Breast Carcinoma In Situ Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Carcinoma in Situ Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Tamoxifen Toremifene Letrozole Anastrozole Exemestane |
Citric Acid Sodium Citrate Anticoagulants Calcium Chelating Agents Chelating Agents Sequestering Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Aromatase Inhibitors Steroid Synthesis Inhibitors Enzyme Inhibitors Estrogen Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |